Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 799

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 799
---
 effect is anti -dilutive. The Company’s potential common shares consist of warrants, convertible promissory notes and convertible loans with their potential dilutive effect considered using the treasury stock method. For the year ended December 31, 2023, 5,747,127common shares from pre -fundedwarrants were added and 3,242,887treasury shares were excluded from the computation. For the year ended December 31, 2022, 13,297,916common shares from warrants were excluded from the computation. For the year ended December 31, 2021, 5,409,746, shares from warrants and 1,474,853treasury shares were excluded from the computation, respectively. Treasury Shares Treasury shares are purchased at cost and recognized as a deduction from equity. Income or loss from subsequent sales is presented in equity. Annex F-128 NLS PHARMACEUTICS LTD.
NOTES TO THE FINANCIAL STATEMENTS

Segment Reporting The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. All of the Company’s tangible assets are held in Switzerland. Recently Issued Accounting Standards Not Yet Effective The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note 3

Prepaid Expenses and Other Current Assets:

The Company’s prepaid expenses and other current assets consisted of the following as of December 31, 2023, and 2022:

|                                                 |     | December 31, |    2023 |     |   |    2022 |
|:------------------------------------------------|:----|:-------------|--------:|:----|:--|--------:|
| Vendor prepayments                              |     | $            | 821,266 |     | $ |  65,739 |
| VAT recoverable and other current assets        |     |              |  24,433 |     |   |  41,243 |
| Other short-term receivables                    |     |              |  10,664 |     |   |       — |
| Prepaid insurance                               |     |              |  69,019 |     |   |  36,